Compare Biogen Inc (BIIB) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Nomura Holdings Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Nomura Holdings Inc trades at $9.8 (market cap $28.46B). The key difference: Biogen Inc and Nomura Holdings Inc are close in size by market cap, and Nomura Holdings Inc pays a 3.31% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | NMR | |
|---|---|---|
Market Cap | $30.13B | $28.46B |
Sector | Health | Financials |
52-Week High | $216.63 | $10.04 |
52-Week Low | $128.93 | $6.73 |
Enterprise Value | $37.20B | — |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Nomura Holdings (NMR) trades at $9.925, up 1.07% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong revenue growth, with 2025 revenue reaching $1.66 trillion and net income of $340.74 billion, yielding a net margin of 20.4%. Recent earnings show a mix of beats and misses, with Q2 2026 EPS beating expectations. Analyst consensus leans toward Hold, with 66.67% of coverage recommending Hold and 33.33% Buy.
The outlook for NMR is supported by robust profitability and valuation metrics like a P/E of 11.59, suggesting potential undervaluation. However, risks include inconsistent cash flow from operations, rising debt-to-asset ratios, and macroeconomic sensitivity. Investors should weigh solid fundamentals against cash flow volatility and debt trends for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
